• Biol. Pharm. Bull. · Jan 2012

    Significant association between hand-foot syndrome and efficacy of capecitabine in patients with metastatic breast cancer.

    • Yuichiro Azuma, Kojiro Hata, Kimie Sai, Ryoko Udagawa, Akihiro Hirakawa, Masahiro Tohkin, Yasuaki Ryushima, Yoshinori Makino, Nobuaki Yokote, Norifumi Morikawa, Yasuhiro Fujiwara, Yoshiro Saito, and Hirosh... more i Yamamoto. less
    • Division of Medicinal Safety Science, National Institute of Health Sciences, Tokyo, Japan.
    • Biol. Pharm. Bull. 2012 Jan 1; 35 (5): 717-24.

    AbstractCapecitabine, an oral prodrug of 5-fluorouracil (5-FU), is a promising treatment for colorectal, breast and gastric cancers, but often causes hand-foot syndrome (HFS), the most common dose-limiting toxicity. The current study was conducted to investigate the relationship between HFS and efficacy of capecitabine in 98 patients with metastatic breast cancer. Possible associations between HFS and efficacy endpoints, including time-to-treatment failure (TTF), tumor response in metastatic lesions and changes in tumor markers, were investigated retrospectively using electronic medical records. The TTF of group with HFS of grade 1 and ≥2 was significantly longer than that of group with no HFS, respectively (hazard ratio (HR), 0.39; 95% confidence interval (CI), 0.18-0.87 for group with grade 1; HR, 0.42, 95% CI, 0.19-0.90 for group with grade ≥2). Significantly higher disease control rates for the liver metastasis were observed in patients with HFS (grade 1 and greater) than in those without HFS (92.9 vs. 42.9%, p=0.009). Furthermore, prevention of increases in tumor marker levels (carcinoembryonic antigen (CEA), carbohydrate antigen 15-3 (CA15-3) and National Cancer Center-Stomach-439 (NCC-ST439)) was evident in patients with HFS. This study clearly showed a significant correlation between HFS and some efficacy markers of capecitabine therapy in patients with metastatic breast cancer, and suggests that early dose adjustment based on severity of HFS might improve efficacy. Studies are needed to explore predictive biomarkers for HFS/efficacy, so that capecitabine therapy can be further tailored to patient response.

      Pubmed     Free full text   Copy Citation  

      Add institutional full text...

    Notes

    hide…

Want more great medical articles?

Keep up to date with a free trial of metajournal, personalized for your practice.
1,694,794 articles already indexed!

We guarantee your privacy. Your email address will not be shared.